Sofinnova’s Maha Katabi on recent M&A and IPO success and how deal flow has ‘never been any better’
Maha Katabi has had a great three months. The Sofinnova general partner has been in the boardroom of two recent M&A exits: radiopharmaceuticals maker RayzeBio, sold to Bristol Myers Squibb, and asthma startup Aiolos Bio, to GSK.
Katabi, who joined Sofinnova in 2019 after roles at Oxalis Capital and Sectoral Asset Management, is one of the leaders of the third-most active investor in private biotech financings last year, per a January report from investment bank William Blair. Sofinnova also recently led a $170 million Series D for BioAge to run mid-stage obesity trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
